Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the period ending June 30, 2026. The report details the announcement of new radiographic data from Week 104 of the pivotal ApproaCH Trial for TransCon CNP (navepegritide), a once-weekly treatment for children with achondroplasia. The data were presented at the 12th International Conference on Children's Bone Health (ICCBH 2026).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements.
Material Changes and Clinical Results
The filing reports significant clinical progress regarding lower extremity alignment in children treated with TransCon CNP over a two-year period (Week 104):
- Tibial-Femoral Angle (TFA) Improvement: In children treated with TransCon CNP during the double-blind period, the average TFA decreased from 9.1° at baseline to 6.9° at Week 104 (mean absolute change of -2.2 degrees).
- Subgroup with Genu Varum: In children with baseline TFA ≥ 5°, the average TFA decreased from 13.4° at baseline to 9.6° at Week 104 (mean absolute change of -3.8 degrees).
- Placebo Switchers: Children switching from placebo to TransCon CNP at Week 52 showed a mean absolute TFA change of -1.7 degrees during the open-label extension period.
- Z-Score Improvements: Mean TFA Z-scores decreased from 3.62 at baseline to 2.96 at Week 104 in the overall treated group.
- Growth Velocity: Improvements in annualized growth velocity were maintained, and ACH-specific height Z-scores increased through Week 104.
- Proportional Growth: The fibula-to-tibia length ratio remained stable, reflecting proportional growth of the lower leg.
Outlook, Risks, and Safety Profile
Safety and Tolerability: Through up to two years of treatment, TransCon CNP was generally well tolerated. The filing notes a low rate of injection site reactions (all mild), no symptomatic hypotension, and no acceleration of bone age. Most adverse events were mild or moderate, with none leading to treatment discontinuation or withdrawal.
Management Commentary: The data supports the continued improvement in lower extremity alignment, specifically in children with preexisting genu varum.
Risks and Contingencies: The filing does not explicitly list new material risks or contingencies beyond the standard clinical trial context.
Key Facts for Investor Verification
- Verify the regulatory status of TransCon CNP (navepegritide) for achondroplasia following the Week 104 data release.
- Confirm the timeline for potential regulatory submissions or approvals based on the sustained efficacy data.
- Monitor the company's financial reports for the impact of this clinical milestone on future revenue projections, as no financial data is present in this filing.
- Review the full safety profile details in the complete clinical study report to assess long-term tolerability.